Radiotherapy in Primary Mediastinal Lymphoma
Completed
- Conditions
- Adjuvant Radiotherapy on Complete Remission Patients
- Interventions
- Radiation: no drugs
- Registration Number
- NCT01230008
- Lead Sponsor
- Instituto Mexicano del Seguro Social
- Brief Summary
The use of Rituximab has been proposed to be useful and avoid the use of radiotherapy in diffuse large B-cell lymphoma with bulky disease.We assess efficacy of adjuvant radiotherapy in patients treated with R-CHOP
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 198
Inclusion Criteria
Diagnosis of primary mediastinal lymphoma No previous treatment performance status < 2 HIV, Hepatis B and C negative Normal :Renal, hepatic, pulmonary and cardiac function
Exclusion Criteria
pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Radiotherapy in primary mediastinal lymphoma no drugs Patients with primary mediastinal lymphoma will be treated with R-CHOP as induction therapy, if complete response is achieved, they were allocated to received or no (control group) adjuvatn radiotherapy, 3.5 G to mediastinal site.
- Primary Outcome Measures
Name Time Method measurement of progression free-survival and overall survival at > 5 years 5 years Assess if the use of adjuvant radiotherapy improve outcome in patients with primary mediastinal lymphoma treated initially with R-CHOP
- Secondary Outcome Measures
Name Time Method assess toxicity secondary to mediastinal radiotherapy > 5 years Assess if the addition of mediastinal radiotherapy to patients who received anthracyclines can produce an increase in cardiac toxicity
Trial Locations
- Locations (1)
Oncology Research Unit
🇲🇽Mèxico DF, DF, Mexico